Skip to main content
Erschienen in: Annals of Surgical Oncology 6/2018

20.03.2018 | Pancreatic Tumors

What is the Incidence of Malignancy in Resected Intraductal Papillary Mucinous Neoplasms? An Analysis of Over 100 US Institutions in a Single Year

verfasst von: Rym El Khoury, MD, Christopher Kabir, MS, Vijay K. Maker, MD, Mihaela Banulescu, MSRC, Margaret Wasserman, BSN, RN, Ajay V. Maker, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

A subset of intraductal papillary mucinous neoplasms (IPMNs) will progress to invasive adenocarcinoma, however identifying invasive from non-invasive disease preoperatively remains challenging. The rate of malignancy in resected IPMNs in the US remains unclear.

Objective

We aimed to determine the rate of malignancy and factors associated with high-risk pathology in resected IPMNs.

Methods

The most recent annual cohort of patients undergoing pancreatectomy included in the American College of Surgeons National Surgical Quality Improvement Program were assessed, and contributions of demographics, preoperative laboratory values, and outcome data to level of IPMN dysplasia were analyzed. The main outcomes were incidence of invasive carcinoma or high-grade dysplasia.

Results

Of 5025 pancreatectomies in 1 year, 478 patients underwent pancreatectomy for IPMN. Invasive carcinoma/high-grade dysplasia was identified in 23% of resected lesions, and there was no difference in patient characteristics or type of resection performed in patients with invasive versus non-invasive pathology. Patients with invasive IPMNs presented significantly more often with high liver function tests, >10% weight loss, clinical jaundice and stent placement, and were more likely to undergo an open operation (p = 0.03). There were no differences in perioperative outcomes. Adjusted logistic regression identified an association between invasive disease and non-soft pancreatic gland texture (odds ratio 0.19, 95% confidence interval 0.05–0.68, p < 0.01).

Conclusions

Approximately 10% of all pancreatectomies in the US are for IPMNs. In these patients, treated after the revised international consensus guidelines, only 23% of IPMNs contained invasive or high-grade histology. Resections carried similar morbidity regardless of pathology. Improved biomarkers are needed to aid in surgical selection.
Literatur
1.
Zurück zum Zitat Fernández-del Castillo C, Targarona J, Thayer SP, et al. Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg. 2003;138(4):427–34; discussion 433–4.CrossRefPubMedPubMedCentral Fernández-del Castillo C, Targarona J, Thayer SP, et al. Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg. 2003;138(4):427–34; discussion 433–4.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Moris M, Bridges MD, Pooley RA, et al. Association between advances in high-resolution cross-section imaging technologies and increase in prevalence of pancreatic cysts from 2005 to 2014. Clin Gastroenterol Hepatol. 2016;14(4):585–93.CrossRefPubMed Moris M, Bridges MD, Pooley RA, et al. Association between advances in high-resolution cross-section imaging technologies and increase in prevalence of pancreatic cysts from 2005 to 2014. Clin Gastroenterol Hepatol. 2016;14(4):585–93.CrossRefPubMed
3.
Zurück zum Zitat Schnelldorfer T, Sarr MG, Nagorney DM, et al. Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas. Arch Surg. 2008;143(7):639–46; discussion 646.CrossRefPubMed Schnelldorfer T, Sarr MG, Nagorney DM, et al. Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas. Arch Surg. 2008;143(7):639–46; discussion 646.CrossRefPubMed
4.
Zurück zum Zitat Farnell MB. Surgical management of intraductal papillary mucinous neoplasm (IPMN) of the pancreas. J Gastrointest Surg. 2008;12(3):414–6.CrossRefPubMed Farnell MB. Surgical management of intraductal papillary mucinous neoplasm (IPMN) of the pancreas. J Gastrointest Surg. 2008;12(3):414–6.CrossRefPubMed
5.
Zurück zum Zitat Maker AV, Lee LS, Raut CP, et al. Cytology from pancreatic cysts has marginal utility in surgical decision-making. Ann Surg Oncol. 2008;15(11):3187–92.CrossRefPubMed Maker AV, Lee LS, Raut CP, et al. Cytology from pancreatic cysts has marginal utility in surgical decision-making. Ann Surg Oncol. 2008;15(11):3187–92.CrossRefPubMed
6.
Zurück zum Zitat Suzuki Y, Nakazato T, Yokoyama M, et al. Development and potential utility of a new scoring formula for prediction of malignant intraductal papillary mucinous neoplasm of the pancreas. Pancreas. 2016;45(9):1227–32.CrossRefPubMed Suzuki Y, Nakazato T, Yokoyama M, et al. Development and potential utility of a new scoring formula for prediction of malignant intraductal papillary mucinous neoplasm of the pancreas. Pancreas. 2016;45(9):1227–32.CrossRefPubMed
7.
Zurück zum Zitat Shin SH, Han DJ, Park KT, et al. Validating a simple scoring system to predict malignancy and invasiveness of intraductal papillary mucinous neoplasms of the pancreas. World J Surg. 2010;34(4):776–83.CrossRefPubMed Shin SH, Han DJ, Park KT, et al. Validating a simple scoring system to predict malignancy and invasiveness of intraductal papillary mucinous neoplasms of the pancreas. World J Surg. 2010;34(4):776–83.CrossRefPubMed
8.
Zurück zum Zitat Fujino Y, Matsumoto I, Ueda T, et al. Proposed new score predicting malignancy of intraductal papillary mucinous neoplasms of the pancreas. Am J Surg. 2007;194(3):304–7.CrossRefPubMed Fujino Y, Matsumoto I, Ueda T, et al. Proposed new score predicting malignancy of intraductal papillary mucinous neoplasms of the pancreas. Am J Surg. 2007;194(3):304–7.CrossRefPubMed
9.
Zurück zum Zitat Wilson GC, Maithel SK, Bentrem D, et al. Are the current guidelines for the surgical management of intraductal papillary mucinous neoplasms of the pancreas adequate? A multi-institutional study. J Am Coll Surg. 2017;224(4):461–9.CrossRefPubMed Wilson GC, Maithel SK, Bentrem D, et al. Are the current guidelines for the surgical management of intraductal papillary mucinous neoplasms of the pancreas adequate? A multi-institutional study. J Am Coll Surg. 2017;224(4):461–9.CrossRefPubMed
10.
Zurück zum Zitat Sahora K, Mino-Kenudson M, Brugge W, et al. Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series. Ann Surg. 2013;258(3):466–75.CrossRefPubMed Sahora K, Mino-Kenudson M, Brugge W, et al. Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series. Ann Surg. 2013;258(3):466–75.CrossRefPubMed
11.
Zurück zum Zitat Fritz S, Klauss M, Bergmann F, et al. Pancreatic main-duct involvement in branch-duct IPMNs: an underestimated risk. Ann Surg. 2014;260(5):848–55; discussion 855–6.CrossRefPubMed Fritz S, Klauss M, Bergmann F, et al. Pancreatic main-duct involvement in branch-duct IPMNs: an underestimated risk. Ann Surg. 2014;260(5):848–55; discussion 855–6.CrossRefPubMed
12.
Zurück zum Zitat Reid-Lombardo KM, St Sauver J, Li Z, et al. Incidence, prevalence, and management of intraductal papillary mucinous neoplasm in Olmsted County, Minnesota, 1984–2005: a population study. Pancreas. 2008;37(2):139–44.CrossRefPubMedPubMedCentral Reid-Lombardo KM, St Sauver J, Li Z, et al. Incidence, prevalence, and management of intraductal papillary mucinous neoplasm in Olmsted County, Minnesota, 1984–2005: a population study. Pancreas. 2008;37(2):139–44.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Fernández-del Castillo C, Warshaw AL. Cystic tumors of the pancreas. Surg Clin N Am. 1995;75(5):1001–16.CrossRefPubMed Fernández-del Castillo C, Warshaw AL. Cystic tumors of the pancreas. Surg Clin N Am. 1995;75(5):1001–16.CrossRefPubMed
14.
Zurück zum Zitat Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006;6(1–2):17–32.CrossRefPubMed Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006;6(1–2):17–32.CrossRefPubMed
15.
Zurück zum Zitat Tanaka M, Fernández-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12(3):183–97.CrossRefPubMed Tanaka M, Fernández-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12(3):183–97.CrossRefPubMed
16.
Zurück zum Zitat Fink AS, Campbell DA Jr, Mentzer RM Jr, et al. The National Surgical Quality Improvement Program in non-veterans administration hospitals: initial demonstration of feasibility. Ann Surg. 2002;236(3):344–53; discussion 353-4.CrossRefPubMedPubMedCentral Fink AS, Campbell DA Jr, Mentzer RM Jr, et al. The National Surgical Quality Improvement Program in non-veterans administration hospitals: initial demonstration of feasibility. Ann Surg. 2002;236(3):344–53; discussion 353-4.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Shimizu Y, Yamaue H, Maguchi H, et al. Predictors of malignancy in intraductal papillary mucinous neoplasm of the pancreas: analysis of 310 pancreatic resection patients at multiple high-volume centers. Pancreas. 2013;42(5):883–8.CrossRefPubMed Shimizu Y, Yamaue H, Maguchi H, et al. Predictors of malignancy in intraductal papillary mucinous neoplasm of the pancreas: analysis of 310 pancreatic resection patients at multiple high-volume centers. Pancreas. 2013;42(5):883–8.CrossRefPubMed
18.
Zurück zum Zitat Hackert T, Fritz S, Klauss M, et al. Main-duct intraductal papillary mucinous neoplasm: high cancer risk in duct diameter of 5 to 9 mm. Ann Surg. 2015;262(5):875–80; discussion 880–1.CrossRefPubMed Hackert T, Fritz S, Klauss M, et al. Main-duct intraductal papillary mucinous neoplasm: high cancer risk in duct diameter of 5 to 9 mm. Ann Surg. 2015;262(5):875–80; discussion 880–1.CrossRefPubMed
19.
Zurück zum Zitat Fan F, Lai EC, Xie F, Yang JM, et al. Intraductal papillary mucinous neoplasms of the pancreas–predictors of malignancy. Hepatogastroenterology. 2010;57(99–100):635–9.PubMed Fan F, Lai EC, Xie F, Yang JM, et al. Intraductal papillary mucinous neoplasms of the pancreas–predictors of malignancy. Hepatogastroenterology. 2010;57(99–100):635–9.PubMed
20.
Zurück zum Zitat Jang JY, Kim SW, Ahn YJ, et al. Multicenter analysis of clinicopathologic features of intraductal papillary mucinous tumor of the pancreas: is it possible to predict the malignancy before surgery? Ann Surg Oncol. 2005;12(2):124–32.CrossRefPubMed Jang JY, Kim SW, Ahn YJ, et al. Multicenter analysis of clinicopathologic features of intraductal papillary mucinous tumor of the pancreas: is it possible to predict the malignancy before surgery? Ann Surg Oncol. 2005;12(2):124–32.CrossRefPubMed
21.
Zurück zum Zitat Kim JR, Jang JY, Kang MJ, et al. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas. J Hepatobiliary Pancreat Sci. 2015;22(9):699–707.CrossRefPubMed Kim JR, Jang JY, Kang MJ, et al. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas. J Hepatobiliary Pancreat Sci. 2015;22(9):699–707.CrossRefPubMed
22.
Zurück zum Zitat Maire F, Voitot H, Aubert A, et al. Intraductal papillary mucinous neoplasms of the pancreas: performance of pancreatic fluid analysis for positive diagnosis and the prediction of malignancy. Am J Gastroenterol. 2008;103(11):2871–7.CrossRefPubMed Maire F, Voitot H, Aubert A, et al. Intraductal papillary mucinous neoplasms of the pancreas: performance of pancreatic fluid analysis for positive diagnosis and the prediction of malignancy. Am J Gastroenterol. 2008;103(11):2871–7.CrossRefPubMed
23.
Zurück zum Zitat Honselmann KC, Patino M, Mino-Kenudson M, et al. Ductal carcinoma arising in a largely unchanged presumed branch-duct IPMN after 10 years of surveillance. Ann Surg. 2017;266(6):e38–40.CrossRefPubMed Honselmann KC, Patino M, Mino-Kenudson M, et al. Ductal carcinoma arising in a largely unchanged presumed branch-duct IPMN after 10 years of surveillance. Ann Surg. 2017;266(6):e38–40.CrossRefPubMed
24.
Zurück zum Zitat Maker AV, Katabi N, Gonen M, et al. Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas. Ann Surg Oncol. 2011;18(1):199–206.CrossRefPubMed Maker AV, Katabi N, Gonen M, et al. Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas. Ann Surg Oncol. 2011;18(1):199–206.CrossRefPubMed
25.
Zurück zum Zitat Maker AV, Katabi N, Qin LX, et al. Cyst fluid interleukin-1beta (IL1beta) levels predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res. 2011;17(6):1502–8.CrossRefPubMedPubMedCentral Maker AV, Katabi N, Qin LX, et al. Cyst fluid interleukin-1beta (IL1beta) levels predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res. 2011;17(6):1502–8.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Maker AV, Carrara S, Jamieson NB, et al. Cyst fluid biomarkers for intraductal papillary mucinous neoplasms of the pancreas: a critical review from the international expert meeting of pancreatic branch-duct-intraductal papillary mucinous neoplasms. J Am Coll Surg. 2015;220(2):243–53.CrossRefPubMed Maker AV, Carrara S, Jamieson NB, et al. Cyst fluid biomarkers for intraductal papillary mucinous neoplasms of the pancreas: a critical review from the international expert meeting of pancreatic branch-duct-intraductal papillary mucinous neoplasms. J Am Coll Surg. 2015;220(2):243–53.CrossRefPubMed
Metadaten
Titel
What is the Incidence of Malignancy in Resected Intraductal Papillary Mucinous Neoplasms? An Analysis of Over 100 US Institutions in a Single Year
verfasst von
Rym El Khoury, MD
Christopher Kabir, MS
Vijay K. Maker, MD
Mihaela Banulescu, MSRC
Margaret Wasserman, BSN, RN
Ajay V. Maker, MD
Publikationsdatum
20.03.2018
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 6/2018
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6425-6

Weitere Artikel der Ausgabe 6/2018

Annals of Surgical Oncology 6/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.